These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31068457)

  • 21. Knockdown of both mitochondrial isocitrate dehydrogenase enzymes in pancreatic beta cells inhibits insulin secretion.
    MacDonald MJ; Brown LJ; Longacre MJ; Stoker SW; Kendrick MA; Hasan NM
    Biochim Biophys Acta; 2013 Nov; 1830(11):5104-11. PubMed ID: 23876293
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutant IDH regulates glycogen metabolism from early cartilage development to malignant chondrosarcoma formation.
    Pathmanapan S; Poon R; De Renshaw TB; Nadesan P; Nakagawa M; Seesankar GA; Ho Loe AK; Zhang HH; Guinovart JJ; Duran J; Newgard CB; Wunder JS; Alman BA
    Cell Rep; 2023 Jun; 42(6):112578. PubMed ID: 37267108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis.
    Stelloo S; Nevedomskaya E; Kim Y; Hoekman L; Bleijerveld OB; Mirza T; Wessels LFA; van Weerden WM; Altelaar AFM; Bergman AM; Zwart W
    Oncogene; 2018 Jan; 37(3):313-322. PubMed ID: 28925401
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation.
    Burd CJ; Petre CE; Morey LM; Wang Y; Revelo MP; Haiman CA; Lu S; Fenoglio-Preiser CM; Li J; Knudsen ES; Wong J; Knudsen KE
    Proc Natl Acad Sci U S A; 2006 Feb; 103(7):2190-5. PubMed ID: 16461912
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MiR-133a-5p inhibits androgen receptor (AR)-induced proliferation in prostate cancer cells via targeting FUsed in Sarcoma (FUS) and AR.
    Zheng L; Kang Y; Zhang L; Zou W
    Cancer Biol Ther; 2020; 21(1):34-42. PubMed ID: 31736422
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines.
    Wang Y; Romigh T; He X; Orloff MS; Silverman RH; Heston WD; Eng C
    Hum Mol Genet; 2010 Nov; 19(22):4319-29. PubMed ID: 20729295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The NLR-related protein NWD1 is associated with prostate cancer and modulates androgen receptor signaling.
    Correa RG; Krajewska M; Ware CF; Gerlic M; Reed JC
    Oncotarget; 2014 Mar; 5(6):1666-82. PubMed ID: 24681825
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IDH2 compensates for IDH1 mutation to maintain cell survival under hypoxic conditions in IDH1‑mutant tumor cells.
    Zhang Y; Lv W; Li Q; Wang Q; Ru Y; Xiong X; Yan F; Pan T; Lin W; Li X
    Mol Med Rep; 2019 Aug; 20(2):1893-1900. PubMed ID: 31257503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Wild-type but not mutant androgen receptor inhibits expression of the hTERT telomerase subunit: a novel role of AR mutation for prostate cancer development.
    Moehren U; Papaioannou M; Reeb CA; Grasselli A; Nanni S; Asim M; Roell D; Prade I; Farsetti A; Baniahmad A
    FASEB J; 2008 Apr; 22(4):1258-67. PubMed ID: 17991730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased RLIP76 expression in IDH1 wild‑type glioblastoma multiforme is associated with worse prognosis.
    Wang Q; Zhang L; Cui Y; Zhang C; Chen H; Gu J; Qian J; Luo C
    Oncol Rep; 2020 Jan; 43(1):188-200. PubMed ID: 31746408
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
    Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
    PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling.
    Wang T; Song W; Chen Y; Chen R; Liu Z; Wu L; Li M; Yang J; Wang L; Liu J; Ye Z; Wang C; Chen K
    Clin Cancer Res; 2016 Mar; 22(6):1531-44. PubMed ID: 26527749
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Constant Degradation of the Androgen Receptor by MDM2 Conserves Prostate Cancer Stem Cell Integrity.
    Vummidi Giridhar P; Williams K; VonHandorf AP; Deford PL; Kasper S
    Cancer Res; 2019 Mar; 79(6):1124-1137. PubMed ID: 30626627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.
    Zhang C; Moore LM; Li X; Yung WK; Zhang W
    Neuro Oncol; 2013 Sep; 15(9):1114-26. PubMed ID: 23877318
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Artemisinin disrupts androgen responsiveness of human prostate cancer cells by stimulating the 26S proteasome-mediated degradation of the androgen receptor protein.
    Steely AM; Willoughby JA; Sundar SN; Aivaliotis VI; Firestone GL
    Anticancer Drugs; 2017 Oct; 28(9):1018-1031. PubMed ID: 28708672
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ING3 promotes prostate cancer growth by activating the androgen receptor.
    Nabbi A; McClurg UL; Thalappilly S; Almami A; Mobahat M; Bismar TA; Binda O; Riabowol KT
    BMC Med; 2017 May; 15(1):103. PubMed ID: 28511652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutant-IDH1-dependent chromatin state reprogramming, reversibility, and persistence.
    Turcan S; Makarov V; Taranda J; Wang Y; Fabius AWM; Wu W; Zheng Y; El-Amine N; Haddock S; Nanjangud G; LeKaye HC; Brennan C; Cross J; Huse JT; Kelleher NL; Osten P; Thompson CB; Chan TA
    Nat Genet; 2018 Jan; 50(1):62-72. PubMed ID: 29180699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The tumor suppressor ING1b is a novel corepressor for the androgen receptor and induces cellular senescence in prostate cancer cells.
    Esmaeili M; Jennek S; Ludwig S; Klitzsch A; Kraft F; Melle C; Baniahmad A
    J Mol Cell Biol; 2016 Jun; 8(3):207-20. PubMed ID: 26993046
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.
    Yepuru M; Wu Z; Kulkarni A; Yin F; Barrett CM; Kim J; Steiner MS; Miller DD; Dalton JT; Narayanan R
    Clin Cancer Res; 2013 Oct; 19(20):5613-25. PubMed ID: 23995860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
    Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
    Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.